


## DBCO-PEG3-SS-NHS ester

|                    |  |       |          |
|--------------------|--|-------|----------|
| Cat. No.:          | HY-133431  |       |          |
| Molecular Formula: | C <sub>34</sub> H <sub>39</sub> N <sub>3</sub> O <sub>9</sub> S <sub>2</sub> |       |          |
| Molecular Weight:  | 697.82   |       |          |
| Target:            | ADC Linker   |       |          |
| Pathway:           | Antibody-drug Conjugate/ADC Related  |       |          |
| Storage:           | Pure form  | -20°C | 3 years  |
|                    |  | 4°C   | 2 years  |
|                    | In solvent   | -80°C | 6 months |
|                    |  | -20°C | 1 month  |



### BIOLOGICAL ACTIVITY

|                           |   |                  |
|---------------------------|---|------------------|
| Description               | DBCO-PEG3-SS-NHS ester is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) <sup>[1]</sup> . DBCO-PEG3-SS-NHS ester is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups. |                  |
| IC <sub>50</sub> & Target | Disulfide Cleavable Linker  | Cleavable Linker |
| In Vitro                  | ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |                  |

### REFERENCES

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA